Steeped in Science.
Loved by Physicians.
Originally crafted for vulnerable post-procedure skin, Colorescience® designs health-forward skincare solutions for women of all ages and skin types, so they feel reassured and confident.
Today, Colorescience is the fastest growing professional skincare brand in the US, leading innovation in sun protection. We expand that innovation into a broad line of skincare and color correction products, in a way that consumers love to wear every day.
We are proud to say every single one of our SPF products has always been, and always will be formulated with only 100% mineral active ingredients—zinc oxide and titanium dioxide—to provide the safest physical protection possible.
Seasoned + Proven Leadership Driving Results
Our executive leadership team has deep expertise in life sciences and innovation, across a varied collection of industries. These seasoned leaders each have a proven track record of driving growth and meaningful financial results within their respective organizations. While we remain laser-focused on building the business, as members of the Colorescience executive team, we are also unified by a passion for the brands mission: protecting lives the safest way we can, one skincare innovation at a time.
MARY FISHER, CHIEF EXECUTIVE OFFICER
SKINMEDICA, ACORDA, CEPHALON, IMMUNEX
STEVE LOOMIS, CHIEF FINANCIAL & OPERATING OFFICER
SKINMEDICA, CARDIODYNAMICS, TERMINAL DATA CORP, KINKOS
TED EBEL, CHIEF BUSINESS OFFICER
SKINMEDICA, AMGEN, CANCERVAX, MP3
CHRISTINA BALESTERI, VP INTERNAL & EXTERNAL CUSTOMERS
PATRICIA BOLAND, VP RESEARCH & DEVELOPMENT
LAURA MERCIER, GURWITCH PRODUCTS
HEATHER GOODCHILD, VP PROFESSIONAL BUSINESS
SKINMEDICA, ALLERGAN, PHARMADERM
JONATHAN FIKSE, EXECUTIVE DIRECTOR FINANCE
LIBERTY DIVERSIFIED INTERNATIONAL, CONSOLIDATED CONTAINER COMPANY, ERNST & YOUNG
BOARD OF DIRECTORS
Rich Aldrich is co-founder and General Partner of Longwood Fund and has spent approximately 35 years as a life sciences entrepreneur and investor. Rich co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline); Concert Pharmaceuticals (NASDAQ: CNCE) where he serves as Chair of the Board; and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), Axial Biotherapeutics, and TScan Therapeutics. Rich also serves as a Director of Longwood portfolio companies Axial, Renovia, and Sitryx Therapeutics.
Prior to co-founding Longwood, Rich founded RA Capital Management, LLC, a life sciences hedge fund, in which he remains an investor. Prior to founding RA Capital Management, LLC, he was a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX) where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to Vertex, he held several management positions at Biogen Inc.
Rich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth College.
Mary is the Chair and Chief Executive Officer at Colorescience, a former division of SkinMedica Inc. where she served as Chief Executive Officer from 2008 until 2012. She led the successful sale of the company to Allergan, Inc. for $350 million with the potential for another $25 million contingent on certain sales milestones.
Mary has spent more than 30 years in the pharmaceutical and biotechnology industries, including management and leadership positions at Acorda Therapeutics, Cephalon, Immunex and Boehringer Ingelheim. She also serves on the board of directors of Sientra and Dermata Therapeutics.
Mary was honored as Ernst & Young's Entrepreneur of the Year for San Diego, California, and received the EY Venture Capital Award of Excellence. She was also recently named a finalist for Most Admired CEO by the San Diego Business Journal.
Ms. Hou is a Managing Director at Montreux Growth Partners and an experienced healthcare investor.
Ms. Hou is actively involved with a number of Montreux’s investments in growth-stage companies. She currently serves on the board of Colorescience and as a board observer at FinPay, Crown Laboratories, and TigerConnect. She previously represented Montreux on the board of SI-BONE(NASDAQ: SIBN) and KFx Medical. She also managed Montreux’s investment in Tobira Therapeutics (NASDAQ: TBRA, acquired by Allergan).
Previously, she was at Quaker Partners, a healthcare investment firm, where she evaluated and executed investments in biopharmaceutical, medical device, diagnostics, healthcare services, and consumer healthcare companies. Prior to joining Quaker, Ms. Hou was a Managing Consultant at Navigant Consulting, where she led and conducted numerous projects in commercial strategy and business development advisory for healthcare clients, including large-cap and specialty pharmaceutical, biotechnology, and healthcare services companies. Ms. Hou also worked in marketing at Abbott on the global launch of its bioresorbable stent. She has contributed to policy and research initiatives supporting regulatory reform with the Medical Innovation and Competitiveness (MedIC) Coalition and National Venture Capital Association(NVCA).
Ms. Hou earned an M.B.A. from Stanford Graduate School of Business and a B.A. in Human Biology and English from Stanford University.
Nicky Kinnaird is a long-time, esteemed innovator in the beauty industry. She revolutionized retail beauty in the early 1990’s with the launch of Space NK Apothecary in London’s Covent Garden. The ground-breaking boutique featured a curated mix of beauty and wellbeing lines and quickly grew into an international beauty mecca—known for offering consumers a unique selection of the finest established and burgeoning brands. Having stepped down from her Space NK duties over 2 years ago, Kinnaird has fed her passion for the evolution of consumer-focused beauty by consulting on growing brands.
Adele Oliva brings decades of finance and healthcare experience to 1315 Capital, including 20 years in private equity focused on commercial stage specialty pharmaceutical, medical technology, and healthcare service investments.
Adele co-founded 1315 Capital in 2015 to establish a firm focused on healthcare growth investing. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.
Forbes recognized Adele on its Midas List of top 100 technology investors worldwide, top 10 life science investors and top women in venture capital.
Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle) and SkinMedica (acquired by Allergan). She currently serves on the boards of Colorescience, Genoptix, Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.
Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates in commercial banking and Baxter Healthcare in marketing and business development.
Adele received a BSc from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.
David Olsen is a Managing Director at Highlander Partners. He leads the company’s efforts in sourcing investments in the beauty and personal care industry and plays an integral strategic role in these businesses post-close. He also works closely with Highlander’s existing CPG-oriented businesses in the areas of product development, branding and channel expansion with an emphasis on digital excellence. David has been a leader in the digital retail space for 20 years.
Since 2016, and just prior to joining Highlander, he served as the CEO of private equity backed Cos Bar, where he brought his digital and ecommerce expertise to transition and grow a traditionally brick-and-mortar beauty retailer into an omni-channel business, while remaining true to its luxury DNA. Prior to Cos Bar, he launched the beauty and grooming businesses at Net-A-Porter and Mr. Porter as Global Vice President, growing those businesses by triple digits annually during his tenure. He originally founded and was the CEO of an e-commerce cosmeceutical business, DermTeam, which he later sold to DermStore, where he went on to lead business development, buying, and operations before selling the business to Target in 2012